

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



ACELRX PHARMACEUTICALS INC Rank 65 of 446



The relative strengths and weaknesses of ACELRX PHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ACELRX PHARMACEUTICALS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 252% points. The greatest weakness of ACELRX PHARMACEUTICALS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 190% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	24,566
Cost of Goods Sold	2,591
Intangible Assets	8,819
Liabilities, Current	13,770
Liabilities, Non-Current	4,805
Other Assets	3,841
Other Compr. Net Income	0
Other Expenses	4,961
Other Liabilities	7,098
Other Net Income	84,401
Other Revenues	1,771
Property and Equipment	10,261
Research and Development	5,193
Selling, General and Administrative Expense	25,672

Output Variable	Value in 1000 USD
Assets	47,487
Liabilities	25,673
Expenses	38,417
Revenues	1,771
Stockholders Equity	21,814
Net Income	47,755
Comprehensive Net Income	47,755
Economic Capital Ratio	233%

